OTC:OTLC | Free Cash Flow | Oncotelic Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2009-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$342,243.00
2025-12-31-$783,017.00
2025-03-31-$166,955.00
2024-12-31-$103,890.00
2024-03-31-$231,416.00
2023-12-31-$372,617.00
2023-03-31-$251,017.00
2022-12-31-$80,680.00
2022-03-31-$962,668.00
2021-12-31-$1.07M
2021-03-31-$1.25M
2020-12-31-$1.49M
2020-03-31$31,473.00
2019-12-31-$944,395.00
2019-03-31-$117,995.00
2018-12-31-$40,045.00
2018-03-31-$882,000.00
2017-12-31-$793,000.00
2017-03-31-$3.7M
2016-12-31-$4.23M
2016-03-31-$4.4M
2015-12-31-$2.97M-$1,000.00-$2.97M
2015-03-31-$3.5M
2014-12-31-$2.85M
2014-03-31-$2.62M
2013-12-31-$2.13M
2013-03-31-$1.89M
2012-12-31-$1.87M
2012-03-31-$2.3M
2011-12-31-$2.81M
2011-03-31-$3.59M
2010-12-31-$2.48M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$1.38M
2024-12-31-$740,277.00
2023-12-31-$1.32M
2022-12-31-$1.45M
2021-12-31-$4.43M
2020-12-31-$2.81M
2019-12-31-$2.28M
2018-12-31-$240,980.00
2017-12-31-$10.93M
2016-12-31-$15.24M
2015-12-31-$11.93M$13,000.00-$11.94M
2014-12-31-$12.15M$17,000.00-$12.17M
2013-12-31-$7M
2012-12-31-$8.34M
2011-12-31-$11.78M
2010-12-31-$20.43M
2009-12-31-$28.67M$109,000.00-$28.78M